NantOmics to Present Analysis on Potential Therapeutic Target in Adenoid Cystic Carcinoma at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Published: Jun 02, 2018

Results to be presented during the head and neck cancer session at the ASCO 2018 Annual Meeting
 

CHICAGO--(BUSINESS WIRE)-- NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present an analysis on how comprehensive molecular profiling with proteomic and genomic analysis revealed CDK6 as a potential therapeutic target in adenoid cystic carcinoma (ACC). This will be presented during the head and neck cancer session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.

“We’re excited to share our analysis on a potential therapy for a form of cancer that rarely responds to chemotherapy or targeted therapy,” said Patrick Soon-Shiong, MD, founder of NantWorks. “There is no standard therapy for advanced ACC, so this is an exciting step toward possibly using comprehensive molecular profiling to help treat patients of this rare secretory gland cancer.”

Presentation Details
Comprehensive molecular profiling with proteomic and genomic analyses reveals CDK6 as a potential therapeutic target in adenoid cystic carcinoma, Abstract #6053
WHO: NantOmics, LLC
WHAT: Head and Neck Cancer Session
WHEN: June 2, 1:15-4:45 PM CST
WHERE: Hall A, McCormick Place

Presentation Summary

This study was conducted in an effort to identify potential alternative therapies for ACC by means other than chemotherapy or targeted therapy. ACC specimens were analyzed with the technology that drives the GPS Cancer test to determine whether comprehensive molecular profiling of ACC tumors could identify targets of FDA-approved or investigational therapies. The results showed that the vast majority of patients did not express any target proteins of FDA-approved targeted therapies, and among solid tumors, breast cancer was closest to ACC based on mRNA expression. The combination of CDK6 overexpression and RB1 proficiency suggested that ACC patients may benefit from CDK6 targeted therapy.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About GPS Cancer™

GPS Cancer™ is a unique, comprehensive test available through NantHealth. GPS Cancer integrates tumor/normal DNA and RNA sequencing, with enhanced expression analysis and bioinformatics of complex biologic pathway systems, including the immune system which provides oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in CLIA-certified and CAP-accredited laboratories. For more information, visit www.gpscancer.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20180602005025/en/

Contacts

NANT
Jen Hodson
jhodson@nantworks.com
or
Henry Jackson, 310-486-8908
cj@nantworks.com

 

Source: NantOmics, LLC
 

Back to news